Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibition and the Future of Lipid Lowering Therapy

Progress in Cardiovascular Diseases

Volumn 58, Issue 1, 2015, Pages 19-31

  Joseph, Lee ^a   Robinson, Jennifer G ^a  

^a UNIVERSITY OF IOWA   (United States)

Author keywords

Hypercholesterolemia; Monoclonal antibodies; Proprotein convertase subtilisin kexin type 9

Indexed keywords

ALIROCUMAB; ANTILIPEMIC AGENT; ATORVASTATIN; BOCOCIZUMAB; EVOLOCUMAB; EZETIMIBE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; PROPROTEIN CONVERTASE SUBTILISIN KEXIN TYPE 9; PROPROTEIN CONVERTASE SUBTILISIN KEXIN TYPE 9 INHIBITOR; ROSUVASTATIN; SUBTILISIN; UNCLASSIFIED DRUG; BIOLOGICAL MARKER; ENZYME INHIBITOR; HYPOCHOLESTEROLEMIC AGENT; MONOCLONAL ANTIBODY; PCSK9 PROTEIN, HUMAN; SERINE PROTEINASE;

ADD ON THERAPY; ARTICLE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; FAMILIAL HYPERCHOLESTEROLEMIA; GENE; GENE EXPRESSION; GENE FREQUENCY; GENE MUTATION; GENOTYPE; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; HYPERCHOLESTEROLEMIA; IMMUNOGENICITY; INJECTION SITE REACTION; MUSCLE DISEASE; NONSENSE MUTATION; PCSK9 GENE; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROTEIN FUNCTION; PROTEIN STRUCTURE; TREATMENT DURATION; ANIMAL; ANTAGONISTS AND INHIBITORS; BLOOD; CARDIOVASCULAR DISEASES; COMPLICATION; ENZYMOLOGY; IMMUNOLOGY; METABOLISM; RISK ASSESSMENT; RISK FACTOR; TREATMENT OUTCOME;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTICHOLESTEREMIC AGENTS; BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; CHOLESTEROL, LDL; ENZYME INHIBITORS; HUMANS; HYPERCHOLESTEROLEMIA; PROPROTEIN CONVERTASES; RISK ASSESSMENT; RISK FACTORS; SERINE ENDOPEPTIDASES; TREATMENT OUTCOME;

EID: 84937635895     PISSN: 00330620     EISSN: 18731740     Source Type: Journal    
DOI: 10.1016/j.pcad.2015.04.004     Document Type: Article

References (76)

1. Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet 2015, 385:117-171. GBD 2013 Mortality and Causes of Death Collaborators.
2. Stone N.J., Robinson J.G., Lichtenstein A.H., et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2014, 63:2889-2934.
3. Grundy S.M. Statin trials and goals of cholesterol-lowering therapy. Circulation 1998, 97:1436-1439.
4. Cholesterol Treatment Trialists' Collaborators, Mihaylova B., Emberson J., et al. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet 2012, 380:581-590.
5. Cannon C. IMProved Reduction of OUtcomes: Vytorin Efficacy International Trial. Presented at the American Heart Association Scientific Sessions, November 17, 2014. Chicago IL 2014, On behalf of the IMPROVE-IT study group.
6. Lipid Modification Clinical Guideline Methods, evidence, and recommendations. February 2014 Draft for consultation. National Institute for Health and Care Excellence, 2014 Accessed March 14, 2014. http://www.nice.org.uk/guidance/index.jsp?action=download&o=66547.
7. American Diabetes Association 8. Cardiovascular disease and risk management. Diabetes Care 2015, 38:S49-S57.
8. Perk J., De Backer G., Gohlke H., et al. European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). Eur Heart J 2012, 33:1635-1701.
9. European Association for Cardiovascular Prevention and Rehabilitation, Reiner Z., Catapano A.L., et al. ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J 2011, 32:1769-1818.
10. Pencina M.J., Navar-Boggan A.M., D'Agostino R.B., et al. Application of new cholesterol guidelines to a population-based sample. N Engl J Med 2014, 370:1422-1431.
11. Paixao A.R.M., Ayers C.R., Berry J.D., de Lemos J.A., Khera A. Atherosclerotic cardiovascular disease prevention: a comparison between the Third Adult Treatment Panel and the New 2013 Treatment of Blood Cholesterol Guidelines. Circ Cardiovasc Qual Outcomes 2014, 7:778-779.
12. Johnson K.M., Dowe D.A. Accuracy of statin assignment using the 2013 AHA/ACC Cholesterol Guideline versus the 2001 NCEP ATP III Guideline: correlation with atherosclerotic plaque imaging. J Am Coll Cardiol 2014, 64:910-919.
13. Puri R., Nissen S.E., Shao M., et al. Impact of baseline lipoprotein and C-reactive protein levels on coronary atheroma regression following high-intensity statin therapy. Am J Cardiol 2014, 114:1465-1472.
14. Boekholdt S.M., Hovingh G.K., Mora S., et al. Very low levels of atherogenic lipoproteins and the risk for cardiovascular events: a meta-analysis of statin trials. J Am Coll Cardiol 2014, 64:485-494.
15. Rosenson R.S., Baker S., Jacobson T., Kopecky S., Parker B. An assessment by the statin muscle safety task force: 2014 update. J Clin Lipidol 2014, 8:S58-S71.
16. Zhang H., Plutzky J., Skentzos S., et al. Discontinuation of statins in routine care settings: a cohort study. Ann Intern Med 2013, 158:526-534.
17. Goff D.C., Lloyd-Jones D.M., Bennett G., et al. 2013 ACC/AHA Guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2014, 63:2935-2959.
18. Investigators A.H., Boden W.E., Probstfield J.L., et al. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med 2011, 365:2255-2267.
19. Group A.S., Ginsberg H.N., Elam M.B., et al. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med 2010, 362:1563-1574.
20. Investigators I-I IMPROVE-IT Trial: a comparison of ezetimibe/simvastatin versus simvastatin monotherapy on cardiovascular outcomes after acute coronary syndromes under Late-Breaking Clinical Trial Abstracts. Circulation 2014, 130:2109.
21. Jones P.H., Nair R., Thakker K.M. Prevalence of dyslipidemia and lipid goal attainment in statin-treated subjects from 3 data sources: a retrospective analysis. J Am Heart Assoc 2012, 1:e001800.
22. Stein E.A., Strutt K., Southworth H., Diggle P.J., Miller E. Comparison of rosuvastatin versus atorvastatin in patients with heterozygous familial hypercholesterolemia. Am J Cardiol 2003, 92:1287-1293.
23. Pijlman A.H., Huijgen R., Verhagen S.N., et al. Evaluation of cholesterol lowering treatment of patients with familial hypercholesterolemia: a large cross-sectional study in the Netherlands. Atherosclerosis 2010, 209:189-194.
24. Abifadel M., Varret M., Rabes J.P., et al. Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nat Genet 2003, 34:154-156.
25. Rashid S., Curtis D.E., Garuti R., et al. Decreased plasma cholesterol and hypersensitivity to statins in mice lacking Pcsk9. Proc Natl Acad Sci U S A 2005, 102:5374-5379.
26. Piper D.E., Jackson S., Liu Q., et al. The crystal structure of PCSK9: a regulator of plasma LDL-cholesterol. Structure 2007, 15:545-552.
27. Seidah N.G., Benjannet S., Wickham L., et al. The secretory proprotein convertase neural apoptosis-regulated convertase 1 (NARC-1): liver regeneration and neuronal differentiation. Proc Natl Acad Sci U S A 2003, 100:928-933.
28. Dietschy J.M., Turley S.D., Spady D.K. Role of liver in the maintenance of cholesterol and low density lipoprotein homeostasis in different animal species, including humans. J Lipid Res 1993, 34:1637-1659.
29. Goldstein J.L., Anderson R.G., Brown M.S. Receptor-mediated endocytosis and the cellular uptake of low density lipoprotein. Ciba Foundation Symposium 92-Membrane Recycling 1982, 77-95. Wiley Online, Library.
30. Horton J.D., Cohen J.C., Hobbs H.H. Molecular biology of PCSK9: its role in LDL metabolism. Trends Biochem Sci 2007, 32:71-77.
31. Seidah N.G. PCSK9 as a therapeutic target of dyslipidemia. Expert Opin Ther Targets 2009, 13:19-28.
32. Mayne J., Dewpura T., Raymond A., et al. Plasma PCSK9 levels are significantly modified by statins and fibrates in humans. Lipids Health Dis 2008, 7:22.
33. Lambert G. Unravelling the functional significance of PCSK9. Curr Opin Lipidol 2007, 18:304-309.
34. Cohen J., Pertsemlidis A., Kotowski I.K., Graham R., Garcia C.K., Hobbs H.H. Low LDL cholesterol in individuals of African descent resulting from frequent nonsense mutations in PCSK9. Nat Genet 2005, 37:161-165.
35. Cohen J.C., Boerwinkle E., Mosley T.H., Hobbs H.H. Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N Engl J Med 2006, 354:1264-1272.
36. Kotowski I.K., Pertsemlidis A., Luke A., et al. A spectrum of PCSK9 alleles contributes to plasma levels of low-density lipoprotein cholesterol. Am J Hum Genet 2006, 78:410-422.
37. Benn M., Nordestgaard B.G., Grande P., Schnohr P., Tybjaerg-Hansen A. PCSK9 R46L, low-density lipoprotein cholesterol levels, and risk of ischemic heart disease: 3 independent studies and meta-analyses. J Am Coll Cardiol 2010, 55:2833-2842.
38. Roth E.M., Diller P. Alirocumab for hyperlipidemia: physiology of PCSK9 inhibition, pharmacodynamics and Phase I and II clinical trial results of a PCSK9 monoclonal antibody. Future Cardiol 2014, 10:183-199.
39. Catapano A.L., Papadopoulos N. The safety of therapeutic monoclonal antibodies: implications for cardiovascular disease and targeting the PCSK9 pathway. Atherosclerosis 2013, 228:18-28.
40. Robinson J.G., Nedergaard B.S., Rogers W.J., et al. Effect of evolocumab or ezetimibe added to moderate- or high-intensity statin therapy on LDL-C lowering in patients with hypercholesterolemia: the LAPLACE-2 randomized clinical trial. JAMA 2014, 311:1870-1882.
41. Sun X., Essalmani R., Day R., Khatib A.M., Seidah N.G., Prat A. Proprotein convertase subtilisin/kexin type 9 deficiency reduces melanoma metastasis in liver. Neoplasia 2012, 14:1122-1131.
42. LaRosa J.C., Pedersen T.R., Somaratne R., Wasserman S.M. Safety and effect of very low levels of low-density lipoprotein cholesterol on cardiovascular events. Am J Cardiol 2013, 111:1221-1229.
43. Hooper A.J., Marais A.D., Tanyanyiwa D.M., Burnett J.R. The C679X mutation in PCSK9 is present and lowers blood cholesterol in a Southern African population. Atherosclerosis 2007, 193:445-448.
44. Zhao Z., Tuakli-Wosornu Y., Lagace T.A., et al. Molecular characterization of loss-of-function mutations in PCSK9 and identification of a compound heterozygote. Am J Hum Genet 2006, 79:514-523.
45. Postmus I., Trompet S., de Craen A.J., et al. PCSK9 SNP rs11591147 is associated with low cholesterol levels but not with cognitive performance or noncardiovascular clinical events in an elderly population. J Lipid Res 2013, 54:561-566.
46. Robinson J.G., Stone N.J. Identifying patients for aggressive cholesterol lowering: the risk curve concept. Am J Cardiol 2006, 98:1405-1408.
47. Baigent C., Keech A., Kearney P.M., et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005, 366:1267-1278.
48. McKenney J.M., Koren M.J., Kereiakes D.J., Hanotin C., Ferrand A.-C., Stein E.A. Safety and efficacy of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease, SAR236553/REGN727, in patients with primary hypercholesterolemia receiving ongoing stable atorvastatin therapy. J Am Coll Cardiol 2012, 59:2344-2353.
49. Roth E.M., McKenney J.M., Hanotin C., Asset G., Stein E.A. Atorvastatin with or without an antibody to PCSK9 in primary hypercholesterolemia. N Engl J Med 2012, 367:1891-1900.
50. Stein E.A., Gipe D., Bergeron J., et al. Effect of a monoclonal antibody to PCSK9, REGN727/SAR236553, to reduce low-density lipoprotein cholesterol in patients with heterozygous familial hypercholesterolaemia on stable statin dose with or without ezetimibe therapy: a phase 2 randomised controlled trial. Lancet 2012, 380:29-36.
51. Stein E.A., Mellis S., Yancopoulos G.D., et al. Effect of a monoclonal antibody to PCSK9 on LDL cholesterol. N Engl J Med 2012, 366:1108-1118.
52. Roth E.M., Taskinen M.-R., Ginsberg H.N., et al. Monotherapy with the PCSK9 inhibitor alirocumab versus ezetimibe in patients with hypercholesterolemia: results of a 24week, double-blind, randomized Phase 3 trial. Int J Cardiol 2014, 176:55-61.
53. Kastelein J.J.P., Langslet G.H., Hovingh G.K., et al. Efficacy and safety of alirocumab in patients with heterozygous familial hypercholesterolemia (heFH) not adequately controlled with current lipid-lowering therapy: results of ODYSSEY FH I and FH II Studies. Late-breaking clinical trial presented at the European Society of Cardiology Congress, Barcelona, Spain 2014.
54. Henry N., Ginsberg D.J.R., Raal Frederick J., et al. ODYSSEY HIGH FH: efficacy and safety of alirocumab in patients with severe heterozygous familial hypercholesterolemia under Late-Breaking Clinical Trial Abstracts. Circulation 2014, 130:2119.
55. Dean J., Kereiakes J.G.R., Cannon Christopher P., et al. Efficacy and safety of alirocumab in high cardiovascular risk patients with suboptimally controlled hypercholesterolemia on maximally tolerated doses of statins: the ODYSSEY COMBO I Study under Late-Breaking Clinical Trial Abstracts. Circulation 2014, 130:2105-2126.
56. Cannon C.C.B., Blom D., McKenney J.M., et al. Efficacy and safety of alirocumab in high cardiovascular risk patients with inadequately controlled hypercholesterolemia on maximally tolerated daily statin: results from the ODYSSEY COMBO II study. Late-breaking clinical trial presented at the European Society of Cardiology Congress, Barcelona, Spain 2014.
57. Harold Bays M.F., Gaudet Daniel, Weiss Robert, et al. Efficacy and safety of combining alirocumab with atorvastatin or rosuvastatin versus statin intensification or adding ezetimibe in high cardiovascular risk patients: ODYSSEY OPTIONS I and II under Late-Breaking Clinical Trial Abstracts. Circulation 2014, 130:2118.
58. Patrick M., Moriarty P.D.T., Christopher P., et al. ODYSSEY ALTERNATIVE: efficacy and safety of the proprotein convertase subtilisin/kexin type 9 monoclonal antibody, alirocumab, versus ezetimibe, in patients with statin intolerance as defined by a placebo run-in and statin rechallenge arm under Late-Breaking Clinical Trial Abstracts. Circulation 2014, 130:2108.
59. Robinson J.G., Farnier M., Krempf M., et al. Long-term safety, tolerability and efficacy of alirocumab versus placebo in high cardiovascular risk patients: first results from the ODYSSEY LONG TERM study in 2,341 patients. Late-breaking clinical trial presented at the European Society of Cardiology Congress, Barcelona, Spain 2014, 2120. [2014 December 2].
60. Schwartz G.G., Bessac L., Berdan L.G., et al. Effect of alirocumab, a monoclonal antibody to PCSK9, on long-term cardiovascular outcomes following acute coronary syndromes: Rationale and design of the ODYSSEY Outcomes trial. Am Heart J 2014, 168:682-9.e1.
61. ODYSSEY Outcomes: Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab SAR236553 (REGN727) Accessed February 15, 2015. https://clinicaltrials.gov/ct2/show/NCT01663402.
62. Dias C.S., Shaywitz A.J., Wasserman S.M., et al. Effects of AMG 145 on low-density lipoprotein cholesterol levels: results from 2 randomized, double-blind, placebo-controlled, ascending-dose phase 1 studies in healthy volunteers and hypercholesterolemic subjects on statins. J Am Coll Cardiol 2012, 60:1888-1898.
63. Giugliano R.P., Desai N.R., Kohli P., et al. Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 in combination with a statin in patients with hypercholesterolaemia (LAPLACE-TIMI 57): a randomised, placebo-controlled, dose-ranging, phase 2 study. Lancet 2012, 380:2007-2017.
64. Raal F., Scott R., Somaratne R., et al. Low-density lipoprotein cholesterol-lowering effects of AMG 145, a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease in patients with heterozygous familial hypercholesterolemia: the Reduction of LDL-C with PCSK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder (RUTHERFORD) randomized trial. Circulation 2012, 126:2408-2417.
65. Sullivan D., Olsson A.G., Scott R., et al. Effect of a monoclonal antibody to PCSK9 on low-density lipoprotein cholesterol levels in statin-intolerant patients: the GAUSS randomized trial. JAMA 2012, 308:2497-2506.
66. Koren M.J., Scott R., Kim J.B., et al. Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 as monotherapy in patients with hypercholesterolaemia (MENDEL): a randomised, double-blind, placebo-controlled, phase 2 study. Lancet 2012, 380:1995-2006.
67. Koren M.J., Lundqvist P., Bolognese M., et al. Anti-PCSK9 monotherapy for hypercholesterolemia: the MENDEL-2 randomized, controlled phase III clinical trial of evolocumab. J Am Coll Cardiol 2014, 63:2531-2540.
68. Raal F.J., Stein E.A., Dufour R., et al. PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial. Lancet 2015, 385:331-340.
69. Stroes E., Colquhoun D., Sullivan D., et al. Anti-PCSK9 antibody effectively lowers cholesterol in patients with statin intolerance: the GAUSS-2 randomized, placebo-controlled phase 3 clinical trial of evolocumab. J Am Coll Cardiol 2014, 63:2541-2548.
70. Blom D.J., Hala T., Bolognese M., et al. A 52-week placebo-controlled trial of evolocumab in hyperlipidemia. N Engl J Med 2014, 370:1809-1819.
71. Koren M.J., Giugliano R.P., Raal F.J., et al. Efficacy and safety of longer-term administration of evolocumab (AMG 145) in patients with hypercholesterolemia: 52-week results from the Open-Label Study of Long-Term Evaluation Against LDL-C (OSLER) randomized trial. Circulation 2014, 129:234-243.
72. Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk (FOURIER) Accessed February 14, 2015. https://clinicaltrials.gov/ct2/show/NCT01764633.
73. Ballantyne C.M., Neutel J., Cropp A., et al. Efficacy and Safety of Bococizumab (RN316/PF-04950615), a monoclonal antibody against proprotein convertase subtilisin/kexin type 9 in statin-treated hypercholesterolemic subjects: Results from a randomized, placebo-controlled, dose-ranging study. J Am Coll Cardiol 2014, 63. A336.
74. The evaluation of bococizumab (PF-04950615; RN316) in reducing the occurrence of major cardiovascular events in high risk subjects (SPIRE-2) Accessed February 15, 2015. https://clinicaltrials.gov/ct2/show/NCT01975389.
75. The evaluation of bococizumab (PF-04950615;RN316) in reducing the occurrence of major cardiovascular events in high risk subjects (SPIRE-1) Accessed February 15, 2015. https://clinicaltrials.gov/ct2/show/NCT01975376.
76. Robinson J.G., Gidding S.S. Curing atherosclerosis should be the next major cardiovascular prevention goal. J Am Coll Cardiol 2014, 63:2779-2785.